Novartis gets US approval for meningitis vaccine
Novartis AG said that its meningitis vaccine Menveo has been approved for use in teenagers and adults by the US Food and Drug Administration.
By Agencies |
Switzerland: Swiss drugmaker Novartis AG said on Monday that its meningitis vaccine Menveo has been approved for use in teenagers and adults by the US Food and Drug Administration (FDA).
Menveo is a vaccine against four common types of bacterial meningitis, which affects between 1,000 and 3,000 people each year in the United States.
The US regulator approved the drug for people between 11 and 55 years, Novartis said.
Bacterial meningitis causes swelling of the membrane that covers the brain or spinal cord and can lead to death within 48 hours.
Novartis said it is continuing clinical trials for the use of the vaccine in other age groups.
The drug received a positive recommendation from the European Union's regulator in December, and Novartis says it expects full EU approval in the coming months.
Menveo is a vaccine against four common types of bacterial meningitis, which affects between 1,000 and 3,000 people each year in the United States.
The US regulator approved the drug for people between 11 and 55 years, Novartis said.
Bacterial meningitis causes swelling of the membrane that covers the brain or spinal cord and can lead to death within 48 hours.
Novartis said it is continuing clinical trials for the use of the vaccine in other age groups.
The drug received a positive recommendation from the European Union's regulator in December, and Novartis says it expects full EU approval in the coming months.
Download
The Economic Times Business News App for the Latest News in Business, Sensex, Stock Market Updates & More.
The Economic Times Business News App for the Latest News in Business, Sensex, Stock Market Updates & More.
Download
The Economic Times News App for Quarterly Results, Latest News in ITR, Business, Share Market, Live Sensex News & More.
The Economic Times News App for Quarterly Results, Latest News in ITR, Business, Share Market, Live Sensex News & More.
ADVERTISEMENT
